A Multicenter Retrospective Study on the Real-World Outcomes of Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma in China

0
0
0

A Multicenter Retrospective Study on the Real-World Outcomes of Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma in China

Peripheral T-cell lymphoma (PTCL) is a group of aggressive blood cancers that behave differently from more common B-cell lymphomas. While PTCL accounts for fewer than 15% of non-Hodgkin lymphoma (NHL) cases in Western countries, it makes up 25–30% of NHL in East Asia—including China—where natural killer/T-cell lymphoma (NK/TCL) is particularly prevalent. For many patients, standard chemotherapy (like CHOP or CHOP-like regimens) isn’t enough to prevent relapse, so hematopoietic stem cell transplantation (HSCT) is often used as a follow-up “consolidation” treatment. But a key question remains: is autologous HSCT (using the patient’s own stem cells) or allogeneic HSCT (using donor stem cells) more effective for PTCL—especially in real-world settings in China?

This study, led by researchers from eight top Chinese hospitals, set out to fill that gap by analyzing real-world outcomes of 128 PTCL patients who received HSCT between 2007 and 2017. The results, published in the Chinese Medical Journal, offer critical insights for patients and doctors navigating this complex treatment choice.

What Did the Study Do?

The research was a multicenter retrospective study—meaning it looked back at existing patient data from eight tertiary hospitals across China (including the Fifth Medical Center of the Chinese PLA General Hospital and Peking University First Hospital). The team included 72 patients who received autologous HSCT (auto-HSCT) and 56 who received allogeneic HSCT (allo-HSCT).

All patients were diagnosed with PTCL using the 2016 World Health Organization (WHO) guidelines, and most first received 6–8 cycles of chemotherapy. Auto-HSCT was typically used for patients who achieved complete (CR) or partial remission (PR) after chemo. Allo-HSCT was reserved for those with relapsed or refractory disease (i.e., chemo didn’t work or cancer came back).

The team tracked key outcomes:

  • Overall survival (OS): How long patients lived after transplant.
  • Progression-free survival (PFS): How long patients lived without cancer coming back or getting worse.
  • Non-relapse mortality (NRM): Death from transplant-related causes (not cancer).
  • Relapse rate: How many patients’ cancer returned after transplant.

Who Were the Patients?

PTCL is biologically diverse, and the study included the four most common subtypes in East Asia:

  1. NK/TCL (37 patients)
  2. ALK-positive anaplastic large cell lymphoma (ALCL) (24 patients)
  3. PTCL-not otherwise specified (PTCL-NOS) (23 patients)
  4. Angioimmunoblastic T-cell lymphoma (AITL) (19 patients)

While the two groups (auto-HSCT vs. allo-HSCT) were similar in age, gender, and subtype distribution, allo-HSCT patients had more unfavorable features:

  • 95% had advanced-stage disease (III–IV) vs. 82% in auto-HSCT.
  • 42% had bone marrow involvement vs. 15% in auto-HSCT.
  • 41% had chemotherapy-resistant disease vs. 8% in auto-HSCT.
  • 32% had progressive disease (PD) at the time of transplant vs. 4% in auto-HSCT.

What Did the Study Find?

After a median follow-up of 30 months (range: 2–143 months), the results showed clear differences between the two transplant types—but outcomes depended heavily on a patient’s health and disease status before transplant.

Overall Outcomes

  • Auto-HSCT had better survival: 70% of auto-HSCT patients were alive 3 years after transplant (vs. 46% of allo-HSCT patients).
  • Auto-HSCT reduced transplant-related death: Only 6% of auto-HSCT patients died from non-cancer causes (like infections or organ damage) vs. 27% of allo-HSCT patients.
  • Relapse rates were similar: 34% of auto-HSCT patients relapsed vs. 29% of allo-HSCT patients—surprising, given allo-HSCT’s “graft-versus-lymphoma” effect (donor cells attacking remaining cancer).

Subgroup Insights: Who Benefits Most from Each Transplant?

The study’s most valuable findings came from breaking down results by prognostic score (PIT, a tool to predict PTCL outcomes) and disease status before transplant:

  1. Lower PIT score = better auto-HSCT outcomes
    Patients with a PIT score of 0–1 (lower risk) who received auto-HSCT in their first remission had a 3-year OS of 85%—far better than patients with a PIT score of 2+ (higher risk), who had a 3-year OS of just 40%. For high-risk patients (PIT 2+), outcomes were similar between auto and allo-HSCT (3-year OS: 40% vs. 34%).

  2. Complete remission (CR) before transplant = auto-HSCT shines
    Patients who achieved CR (no detectable cancer) before auto-HSCT had the best survival: 88% were alive 3 years later, compared to 48% of CR patients who received allo-HSCT.

  3. For non-CR patients, outcomes are similar
    For patients who weren’t in CR (e.g., PR, stable disease, or PD) before transplant, survival rates were comparable between auto and allo-HSCT (3-year OS: 51% vs. 46%). This is notable because allo-HSCT patients in this subgroup had more aggressive disease (e.g., advanced stage, bone marrow involvement) but still achieved results on par with auto-HSCT.

What Does This Mean for Patients and Doctors?

The study—one of the largest real-world analyses of HSCT for PTCL in China—offers practical guidance for treatment decisions:

  • Auto-HSCT is ideal for “good-risk” patients: If you have a lower PIT score or have achieved CR with chemotherapy, auto-HSCT is likely the best choice. It has lower transplant-related risk and better survival.
  • Allo-HSCT is a viable option for “high-risk” patients: If your cancer is advanced, resistant to chemo, or has spread to the bone marrow, allo-HSCT may be worth considering—even though it carries higher risks of complications like graft-versus-host disease (GVHD).

Importantly, the study found no difference in relapse rates between the two transplant types—suggesting that allo-HSCT’s “graft-versus-lymphoma” effect may not outweigh the higher toxicity for all patients. For non-CR patients, however, allo-HSCT’s ability to target remaining cancer may balance out its risks.

Limitations and Next Steps

Like all retrospective studies, this one has caveats:

  • Small sample size: Only 128 patients were included, so results may not apply to all PTCL patients in China.
  • Retrospective design: The study looked back at existing data, which can introduce bias (e.g., doctors may have chosen transplant types based on unmeasured factors).
  • No data on non-transplant patients: The study didn’t include patients who couldn’t receive HSCT (e.g., due to age or health), so it doesn’t reflect the full PTCL patient journey.

Despite these limits, the study provides much-needed real-world data for Chinese clinicians. The next step is prospective, randomized trials to directly compare auto and allo-HSCT in matched patient groups—especially for high-risk patients.

Conclusion

For PTCL patients in China, HSCT remains a critical treatment option—but the choice between auto and allo depends on individual health and disease status. Auto-HSCT is safer and more effective for patients in good condition, while allo-HSCT offers hope for those with aggressive or resistant disease. As one of the first large studies of its kind in China, this work helps bridge the gap between clinical guidelines and real-world practice—bringing patients and doctors one step closer to personalized care.

Original Study Citation:
Gu ZY, Dong YJ, Fu XR, et al. A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China. Chinese Medical Journal. 2021;134(13):1584–1592.
DOI: doi.org/10.1097/CM9.0000000000001575

Study Authors and Institutions:
Zhen-Yang Gu¹, Yu-Jun Dong², Xiao-Rui Fu³, Nai-Nong Li⁴, Yao Liu⁵, Xiao-Xiong Wu¹, Yi-Ni Wang⁶, Yu-Hang Li¹, Han-Yun Ren², Ming-Zhi Zhang³, Xiao-Fan Li⁴, Mai-Hong Wang⁵, Ya-Mei Wu¹, Dai-Hong Liu¹, Zhao Wang⁶, Liang-Ding Hu¹, Wen-Rong Huang¹

  1. Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing
  2. Department of Hematology, Peking University First Hospital, Beijing
  3. Department of Oncology, Zhengzhou University First Affiliated Hospital, Zhengzhou
  4. Department of Hematology, Fujian Institute of Hematology, Fuzhou
  5. Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing
  6. Department of Hematology, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing

Was this helpful?

0 / 0